MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2022 International Congress

    Effect of KW-6356, a novel adenosine A2A receptor antagonist/inverse agonist, on motor and non-motor symptoms in Parkinson’s disease patients as an adjunct to levodopa therapy: Results of Phase 2b study

    T. Maeda, K. Sugiyama, K. Yamada, M. Nishi, N. Hattori (Iwate, Japan)

    Objective: To evaluate the efficacy and safety of KW-6356 in Parkinson’s disease (PD) patients with levodopa therapy, irrespective of the presence of wearing-off (WO). Background:…
  • 2022 International Congress

    Double trouble: Association of malignant melanoma with sporadic and genetic forms of Parkinson’s disease and asymptomatic carriers of related genes in the PPMI study.

    C. Koros, AM. Simitsi, A. Bougea, N. Papagiannakis, I. Pachi, A. Prentakis, R. Antonelou, A. Zahou, I. Beratis, E. Efthymiopoulou, E. Stanitsa, C. Chrysovitsanou, E. Angelopoulou, K. Lourentzos, V. Constantinides, M. Bozi, D. Papadimitriou, A. Bonakis, G. Paraskevas, C. Potagas, S. Papageorgiou, X. Trapali, M. Stamelou, L. Stefanis (Athens, Greece)

    Objective: The aim of the present study was to assess the prevalence of malignant melanoma (MM) in sporadic and genetic Parkinson’s disease (PD) patients and…
  • 2022 International Congress

    Impact of ApoE genotype on cognition in idiopathic and genetic forms of Parkinson’s disease

    C. Koros, K. Brockmann, Aμ. Simitsi, A. Bougea, H. Liu, ακ. Hauser, C. Schulte, I. Pachi, N. Papagiannakis, A. Zahou, I. Wurster, E. Efthymiopoulou, I. Beratis, R. Antonelou, M. Maniati, M. Moraitou, H. Michelakakis, G. Paraskevas, S. Papageorgiou, C. Potagas, D. Papadimitriou, M. Bozi, M. Stamelou, T. Gasser, L. Stefanis (Athens, Greece)

    Objective: The aim of our current report was to assess the impact of Apolipoprotein-E (ApoE) genotype on cognition in idiopathic Parkinson’s disease (PD) patients and…
  • 2022 International Congress

    Juvenile Huntington’s Disease in Tunisia: Clinical Diversity and Literature review

    H. Nehdi, E. Chebbi, F. Nabli, Z. Saied, S. Ben Sassi, R. Amouri (Tunis, Tunisia)

    Objective: We conducted the first JHD clinical and molecular features in Tunisia and North Africa, contributing to better understanding the diverse manifestation of the disease…
  • 2022 International Congress

    Characterization of routine botulinum toxin (BoNT) therapy and patient population in cervical dystonia

    B. Waeschle, H. Stark, P. Albrecht (Düsseldorf, Germany)

    Objective: We conducted a survey to characterize real-world treatment of CD patients with focus on treatment duration, clinical parameters and awareness of clinical resistance as…
  • 2022 International Congress

    Mimics or multiplicity: two patients with a PSP phenotype and underlying genetic neurodegenerative disorders.

    S. Lyons, R. Walsh, T. Lynch, S. O'Dowd (Dublin, Ireland)

    Objective: To describe a two cases of patients presenting with a PSP phenotype and genetic findings consisted with Huntington’s disease (HD) in one case and…
  • 2022 International Congress

    Three patients with PSP presenting with a logopenic pattern of aphasia: expanding the phenotype of language impairment in PSP.

    S. Lyons, R. Walsh, T. Lynch, S. O'Dowd (Dublin, Ireland)

    Objective: To investigate the a series of cases presenting with apparent logopenic variant primary progressive aphasia who then developed symptoms suggestive of PSP. Background: Deficits…
  • 2022 International Congress

    Cognitive and Motor aspects of a Brazilian population with Parkinson´s disease and Impulse Control Disorders and/or Related Behaviors – an observational study.

    B. Veiga, C. da Silva, L. Barcelos, H. Ferraz, S. Silva, V. Borges (São Paulo, Brazil)

    Objective: We analysed if Impulse Control Disorders (ICDs) and/or Related Behaviors (RBs) were associated with levodopa-induced dyskinesia (LIDs) in Brazilian patients with Parkinson´s disease (PD)…
  • 2022 International Congress

    Impact of dopamine replacement therapies on MDS-UPDRS II

    F. Nassan, J. Shirvan, M. Yang, T. Dam, J. Wang, N. Maserejian, W. Flanders (Brookline, USA)

    Objective: To estimate the longitudinal effect of different dopamine therapies on the Movement Disorder Society-Sponsored Unified Parkinson's Disease Rating Scale Part II (MDS-UPDRS II) among…
  • 2022 International Congress

    Sarcopenia Screening with Limb Circumference and Impacts of Sarcopenia in Parkinson’s disease

    SJ. Kim, YJ. Jeong, SM. Cheon ()

    Objective: In this study, we evaluated limb circumference as sarcopenia screening tool in PD and comprehensively investigated the impacts of sarcopenia in PD. Background: Sarcopenia…
  • « Previous Page
  • 1
  • …
  • 501
  • 502
  • 503
  • 504
  • 505
  • …
  • 1554
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley